# Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct07852988` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07852988](<https://clinicaltrials.gov/study/NCT07852988>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07852988

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07852988. Randomized; double masking; primary purpose treatment. Start 2026-08-01 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07852988, source copy `cardio:ctgov-nct07852988-2026-10-01`, retrieved 2026-10-26)
- Started: 2026-08-01 (actual) (ClinicalTrials.gov record NCT07852988, source copy `cardio:ctgov-nct07852988-2026-10-01`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07852988, source copy `cardio:ctgov-nct07852988-2026-10-01`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT07852988, source copy `cardio:ctgov-nct07852988-2026-10-01`, retrieved 2026-10-26)
- Countries: Poland (ClinicalTrials.gov record NCT07852988, source copy `cardio:ctgov-nct07852988-2026-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07852988-2026-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes (T2DM)
- Intervention (Drug): Pancreatin
- Intervention (Drug): Placebo
- Lead sponsor: Silesian Centre for Heart Diseases
- Lead sponsor class: OTHER
- Collaborator: Medical University of Silesia
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Silesian Centre for Heart Diseases (`cardio:org-silesian-centre-for-heart-diseases`)
- Registry lists this organization as a collaborator: Medical University of Silesia (`cardio:org-medical-university-of-silesia`)

## Provenance

Content hash: 6db12288125c41f0db23f65de99af9ee10d8f82bce0138e4e0009ab719812338
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
